We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03351114
Recruitment Status : Completed
First Posted : November 22, 2017
Results First Posted : April 1, 2021
Last Update Posted : April 1, 2021
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Duke University

Brief Summary:
This is a pilot study to determine the safety and clinical efficacy of crisaborole 2% ointment in the treatment of morphea.

Condition or disease Intervention/treatment Phase
Morphea Drug: Crisaborole Phase 2

Detailed Description:

A Phase 2, pilot, proof-of-concept, open label, single arm prospective study to assess the safety, tolerability and efficacy of using crisaborole 2% ointment for adult morphea. Patients identified by their physician, nurse, or other member of their clinical care team as meeting criteria for the study will be asked to apply crisaborole 2% ointment, twice daily, on affected plaques for 12 weeks. A 4 mm skin punch biopsy will be performed at baseline and at 12 weeks, on the same affected plaque. Dermal thickness will be measured and compared before and at the end of treatment. Patients will have a clinical assessment at baseline and at weeks 4, 8 and 12. After week 12, patients who need further treatment will undergo standard of care treatment as determined by their primary dermatologist. Physician and patient reported assessment and skin imaging will be performed at baseline, week 4, 8 and 12, and at week 20. Photography will also be performed at baseline and week 12. An optional post treatment follow-up will be performed at week 20.

Medication will be provided free of charge by Pfizer, as part of the grant that is funding this study. These will be dispensed by the study group at baseline and during the subsequent clinic visits.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea
Actual Study Start Date : September 1, 2018
Actual Primary Completion Date : March 10, 2020
Actual Study Completion Date : March 10, 2020


Arm Intervention/treatment
Experimental: Crisaborole 2% ointment
Crisaborole 2% ointment applied to affected skin twice per day.
Drug: Crisaborole
Apply Crisaborole 2% ointment to affected skin twice per day.
Other Name: Eucrisa




Primary Outcome Measures :
  1. Number of Participants Who Had a Reduction in Dermal Thickness of Sentinel Plaque [ Time Frame: Baseline, 12 weeks ]
    Change in dermal thickness on skin biopsy. A sentinel plaque will be selected at baseline. A 4 mm skin punch biopsy will be performed at baseline and at 12 weeks, on the same affected plaque.


Secondary Outcome Measures :
  1. Percentage of Reduction in DIET Score of Sentinel Plaque [ Time Frame: Baseline and 12 weeks ]
    The DIET (Dyspigmentation, Induration, Erythema, and Telangiectasias) score is a physician-assessed, previously validated score. Range is 0-12, and a higher score denotes increased activity or severity.

  2. Percentage of Reduction in LoSCAT Score [ Time Frame: Baseline,12 weeks ]
    LoSCAT (Localized Scleroderma Cutaneous Assessment Tool ) score is a physician-assessed, previously validated score. It has 2 components, the LoSSI (localized scleroderma skin severity index, range 0-162), which measures disease activity, and LoSDI (localized scleroderma damage index, range 0-216). The higher the number, the higher the disease activity and damage, respectively.

  3. Percentage of Reduction in Skindex-29 Score [ Time Frame: Baseline and 12 weeks ]
    Skindex-29 is a health-related quality of life score; minimum score 30, maximum 150. Lower score indicates a better quality of life.

  4. Change in Dermal Thickness of Sentinel Plaque by Ultrasonography [ Time Frame: Baseline, 4, 8 and 12 weeks, optional at 20 weeks ]
    B-Mode ultrasonographic imaging will be utilized to measure dermal thickness of the sentinel plaque



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. >= 18 years of age
  2. Clinical diagnosis of morphea.
  3. <20% Total body surface area involvement.
  4. Does not require systemic immunosuppressive therapy for morphea.
  5. No immunosuppressive systemic therapy 1 month prior to starting the study (methotrexate, mycophenolate mofetil, azathioprine, cyclosporine, cyclophosphamide, prednisone >=10 mg PO daily).
  6. No immunomodulating topical therapy (topical steroids or topical calcineurin inhibitor), and no topical vitamin D analogue, 2 weeks prior to starting study.
  7. No allergy to crisaborole or vehicle.
  8. No known renal disease
  9. Able to give informed consent.

Exclusion Criteria:Subjects fulfilling any of the following criteria are not eligible for inclusion in this study.

  1. Clinical diagnosis of depression or history of suicidal ideation.
  2. Pregnant or breastfeeding women, with pregnant women being defined as the state of a female after conception until the termination of gestation, confirmed by a positive urine human chorionic gonadotropin (hCG) laboratory test. Women with a positive urine hCG at any time during the study will be withdrawn from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03351114


Locations
Layout table for location information
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Duke University
Pfizer
Investigators
Layout table for investigator information
Principal Investigator: Adela Cardones, MD Duke UMC
  Study Documents (Full-Text)

Documents provided by Duke University:
Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT03351114    
Other Study ID Numbers: Pro00086947
First Posted: November 22, 2017    Key Record Dates
Results First Posted: April 1, 2021
Last Update Posted: April 1, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Duke University:
Morphea, Localized Scleroderma
Additional relevant MeSH terms:
Layout table for MeSH terms
Scleroderma, Localized
Connective Tissue Diseases
Skin Diseases